Hermes Investment Management’s Autolus Therapeutics AUTL Stock Holding History

Hermes Investment Management’s Portfolio AUTL Stock Details AUTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$1.25M	Buy	+46,600	New	+$1.23M	0.02%	168

Other funds holding AUTL

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Hermes Investment Management's AUTL Position: Q2 2018 in Review

Hermes Investment Management opened a new position in Autolus Therapeutics (AUTL) in Q2 2018: 46,600 shares worth $1.25M. The stake represents 0.02% of the portfolio and ranks #168 among its holdings.

48 funds tracked by Wall St. Rank hold AUTL as of Q2 2018.

Hermes Investment Management held 46,600 shares of Autolus Therapeutics worth $1.25M as of Q2 2018.
Autolus Therapeutics was a new Hermes Investment Management position in Q2 2018.
Autolus Therapeutics made up 0.02% of Hermes Investment Management's portfolio in Q2 2018, its #168 holding.
48 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2018.

Based on Hermes Investment Management's 13F filing for Q2 2018, filed 24 Jul 2018.